A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870 (Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)

Trial Profile

A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870 (Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs Nemonoxacin (Primary) ; Levofloxacin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors TaiGen Biotechnology
  • Most Recent Events

    • 03 Dec 2015 According to a TaiGen Biotechnology media release, the Taiwan FDA granted new drug license for the oral formulation of Taigexyn to TaiGen in January 2015.
    • 16 May 2013 Primary endpoint 'Clinical-cure-rate' has been met according to a TaiGen Biotechnology media release.
    • 16 May 2013 Primary endpoint 'Bacteriological-eradication-rate' has been met according to a TaiGen Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top